Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

318 ARTÍCULOS , VIENDO DEL 136 AL 150

Alzheimer disease: what new evidence shows

Uriri-Glover J, McCarthy M, Cesarotti E.

Nurs Manage. 2012 Nov;43(11):26-31; quiz 31-2. doi: 10.1097/01.NUMA.0000421671.10723.ad.

Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress

Castellani RJ, Perry G.

Arch Med Res. 2012 Nov;43(8):694-8. doi: 10.1016/j.arcmed.2012.09.009. Epub 2012 Oct 16.

Drug repositioning for Alzheimer's disease

Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, Kearns I, Kehoe P, Mudher A, Passmore A, Shepherd N, Walsh F, Ballard C.

Nat Rev Drug Discov. 2012 Nov;11(11):833-46. doi: 10.1038/nrd3869.

Alzheimer disease in 2020

Holtzman DM, Mandelkow E, Selkoe DJ.

Cold Spring Harb Perspect Med. 2012 Nov 1;2(11):a011585. doi: 10.1101/cshperspect.a011585.

A concept analysis about temporality and its applicability in nursing care

Caldas CP, Berterö C.

Nurs Forum. 2012 Oct-Dec;47(4):245-52. doi: 10.1111/j.1744-6198.2012.00277.x.

Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins

Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB.

Arch Med Res. 2012 Nov;43(8):699-704. doi: 10.1016/j.arcmed.2012.10.010. Epub 2012 Nov 3.

Introductory remarks. Molecular, biological and clinical aspects of Alzheimer's disease

Maccioni RB.

Arch Med Res. 2012 Nov;43(8):593-4. doi: 10.1016/j.arcmed.2012.11.001. Epub 2012 Nov 10.

[Montessori method applied to dementia - literature review]

Brandão DF, Martín JI.

Rev Gaucha Enferm. 2012 Jun;33(2):197-204. doi: 10.1590/s1983-14472012000200027.

Current therapeutic strategy in Alzheimer's disease

Singh S, Kushwah AS, Singh R, Farswan M, Kaur R.

Eur Rev Med Pharmacol Sci. 2012 Nov;16(12):1651-64.

Alzheimer's disease: development of disease-modifying treatments is the challenge for our generation

Lindsley CW.

ACS Chem Neurosci. 2012 Nov 21;3(11):804-5. doi: 10.1021/cn300190f.

Life orientation in Finnish family caregivers' of persons with Alzheimer's disease: a diary study

Välimäki T, Vehviläinen-Julkunen K, Pietilä AM, Koivisto A.

Nurs Health Sci. 2012 Dec;14(4):480-7. doi: 10.1111/j.1442-2018.2012.00721.x.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease

Francis PT, Parsons CG, Jones RW.

Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124.

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice

Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D, Silvestri E, Canzoniero LM, Sekler I, Pandolfi A, Sensi SL.

Cell Death Dis. 2012 Dec 20;3(12):e448. doi: 10.1038/cddis.2012.189.

[Tacrine and its derivatives in the therapy of Alzheimers disease]

Korábečný J, Spilovská K, Benek O, Musílek K, Soukup O, Kuča K.

Ceska Slov Farm. 2012 Oct;61(5):210-21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias